Summary of Key Points from the Conference Call Company Overview - **Company Name**: Jin Ai Holdings - **Industry**: AI-driven pharmaceutical discovery and automation solutions - **Core Business**: 85% drug discovery, 15% smart automation solutions [2][3] Core Insights and Arguments - **Technology Utilization**: Jin Ai Holdings leverages quantum physics and AI to enhance drug discovery, significantly improving the efficiency of AI model training and reducing the drug development cycle to 2 years [2][3] - **Revenue Model**: The company generates revenue through R&D service fees, milestone payments, and sales sharing, focusing on high-margin services [2][3] - **Partnerships**: In 2025, Jin Ai Holdings signed a total of $6.25 billion in orders with Eli Lilly, including $250 million for small molecules and $6 billion for large molecules, and entered into a collaboration with Gan Li Pharmaceutical in the peptide metabolism field [4] - **Non-Pharmaceutical Ventures**: The company is expanding into non-drug areas, collaborating with Sinopec, Peking University, and JW Pharmaceutical, and has formed a joint venture with Jinko Solar to develop perovskite tandem solar cells, expected to achieve mass production by 2028 [2][5][8] Important Developments - **Hair Growth Product**: Jin Ai Holdings launched a self-developed hair growth product, which received FDA approval and is expected to gain domestic raw material registration by 2026. The product is priced at 389 RMB and has shown a high efficacy rate in clinical trials [6][7] - **Market Potential**: Approximately 2.5 billion people globally face hair loss issues, indicating a significant market opportunity for the hair growth product [6] - **Automation Laboratory**: The company’s automated laboratory is set to enhance data quality and efficiency, with plans to implement it by the end of 2024 [3][12] Competitive Advantages - **Data Generation**: Jin Ai Holdings' quantum physics-based AI model can generate large-scale data for training, allowing breakthroughs in data-scarce areas, outperforming 90% of commercial software in the market [3][11] - **Flexibility in Business Model**: Unlike traditional pharmaceutical companies, Jin Ai Holdings does not bear the risks of clinical development, allowing for a more flexible and efficient revenue growth strategy [10][11] - **Collaboration with Major Firms**: The company maintains strong partnerships with major pharmaceutical firms like Eli Lilly and technology companies like NVIDIA, focusing on collaborative projects rather than direct competition [14][15] Future Outlook - **R&D Efficiency**: AI in drug discovery is expected to enhance efficiency and reduce costs by generating millions of small molecules and significantly speeding up the testing process through automation [16][17] - **Perovskite Solar Cells**: The joint venture with Jinko Solar aims to address the challenges of perovskite solar cells, with a focus on improving stability and performance for potential space applications [8] This summary encapsulates the key points discussed in the conference call, highlighting Jin Ai Holdings' innovative approach, strategic partnerships, and future growth potential in both pharmaceutical and non-pharmaceutical sectors.

摘要 京泰控股构建了全球唯一的 AI 驱动的闭环生态系统，通过量子物理理论 设计分子结构，并利用机器人实验室产生高质量数据，验证并训练 AI 模 型，从而在物质发现领域保持领先地位。 公司深耕生物医药行业，与辉瑞、礼来等全球 Top20 药企建立了合作关 系，例如与辉瑞合作开发新冠口服特效药 Paxlovid，并与礼来在小分子、 大分子药物领域展开合作，获得技术平台授权使用费。 京泰控股的商业模式是为客户提供从靶点发现到临床前候选化合物阶段 的服务，收取服务费，并在管线授权后获得里程碑费用和销售分成，覆 盖产品全生命周期。 公司 AI 和机器人技术大幅提升药物研发效率，将传统 4-6 年的研发周期 压缩至两年以内，并能设计出更具新颖性的分子，突破人类经验局限。 京泰控股的大分子技术平台 Astex Fold 基于动态蛋白训练，在特定疾 病类型中准确度超过 AlphaFold，已与强生、优时比等公司达成合作， 并与礼来达成 3.45 亿美元的大规模合作协议。 公司积累了 2,600 万条化学反应数据，通过高通量技术和自动化系统持 续产生高质量数据，模型成功率超过 90%，显著优于行业水平。 京泰控股正将 AI ...

Core Viewpoint - Crown Holdings (01872) announced the signing of two non-binding memorandums of understanding by its wholly-owned subsidiary AlphaMind AI, aimed at acquiring exclusive rights to significant patents and trademarks related to innovative products in the cosmetic and pharmaceutical sectors [1][2][3] Group 1: Agreements and Intellectual Property - The first memorandum is with Shenzhen Jingtai, which holds two major patent applications related to compounds and their uses, specifically CN202311128222.7 and CN202311247312.8 [1] - The second memorandum is with Shenzhen Liziruiya, which currently owns or is applying for trademarks related to the "Groland" brand and has obtained exclusive rights to a patent from Shenzhen Jingtai [2] - AlphaMind AI intends to acquire exclusive global licenses for the target intellectual property, allowing it to develop, manufacture, use, sell, and import the target compounds XTP-118 and XTP-016 [1][2] Group 2: Product Development and Innovations - The target intellectual property includes proprietary technology and key raw materials essential for cosmetic formulations, particularly for hair growth products [2] - The project team at Shenzhen Jingtai has achieved three significant innovations in hair growth product development, including a breakthrough "cultivation" solution based on follicle microbiology, an innovative formulation design method combining AI and robotics, and unique improvements in delivery methods using nanotechnology [2] - The first-generation product has already been launched in Taiwan under the target trademark, while the second-generation product is planned for production in Singapore [3] Group 3: Strategic Business Development - The company is actively exploring opportunities to acquire rights related to the target intellectual property, trademarks, and licenses, which will enable it to operate globally in the hair growth product market [3] - The management team is establishing a comprehensive business model, building a professional network, detailing implementation strategies, and planning initial investments [3]